Heterogeneity and treatment landscape of ovarian carcinoma

AC Veneziani, E Gonzalez-Ochoa, H Alqaisi… - Nature Reviews …, 2023 - nature.com
Ovarian carcinoma is characterized by heterogeneity at the molecular, cellular and
anatomical levels, both spatially and temporally. This heterogeneity affects response to …

[HTML][HTML] Prevention, screening, treatment and follow-up of gynecological cancers: state of art and future perspectives

TG D'Augè, A Giannini, G Bogani, C Di Dio… - Clinical and …, 2023 - imrpress.com
Objective: This study aims to analyze the available data on prevention and early diagnosis
in gynecological cancers. Mechanism: A comprehensive search was performed in the …

CT-based radiomics and deep learning for BRCA mutation and progression-free survival prediction in ovarian cancer using a multicentric dataset

G Avesani, HE Tran, G Cammarata, F Botta… - Cancers, 2022 - mdpi.com
Simple Summary Ovarian cancer has a heterogeneous response to treatment, and relapse
may vary considerably. Different studies investigated the role of radiomics in ovarian cancer …

Expanding the Role of Boron in New Drug Chemotypes: Properties, Chemistry, Pharmaceutical Potential of Hemiboronic Naphthoids

MZH Kazmi, OM Schneider, DG Hall - Journal of Medicinal …, 2023 - ACS Publications
New chemotypes and bioisosteres can open a new chemical space in drug discovery and
help meet an urgent demand for novel agents to fight infections and other diseases. With the …

PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages

DV Santinelli-Pestana, E Aikawa, SA Singh, M Aikawa - Pathogens, 2023 - mdpi.com
Aberrant adenosine diphosphate-ribose (ADP)-ribosylation of proteins and nucleic acids is
associated with multiple disease processes such as infections and chronic inflammatory …

Role of PARP inhibitors in cancer immunotherapy: potential friends to immune activating molecules and foes to immune checkpoints

O Franzese, G Graziani - Cancers, 2022 - mdpi.com
Simple Summary This review aims at analyzing an emergent topic regarding the possible
combined use of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), anticancer drugs …

Immunotherapeutic approaches in ovarian cancer

H Yoon, A Kim, H Jang - Current Issues in Molecular Biology, 2023 - mdpi.com
Ovarian cancer (OC) is gynecological cancer, and diagnosis and treatment are continuously
advancing. Next-generation sequencing (NGS)-based diagnoses have emerged as novel …

Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced …

A Llueca, MV Ibañez, P Cascales, A Gil-Moreno… - Cancers, 2023 - mdpi.com
Simple Summary Advanced ovarian cancer (Stages III-IV) continues to be one of the
gynecological tumors with the highest mortality. Standard treatment consists of debulking …

Addition of niraparib to best supportive care as maintenance treatment in patients with advanced urothelial carcinoma whose disease did not progress after first-line …

F Vignani, R Tambaro, U De Giorgi, P Giannatempo… - European urology, 2023 - Elsevier
Background Platinum-based chemotherapy (PBCT) is the standard first-line treatment for
advanced urothelial carcinoma (UC). Potential cross-sensitivity can be hypothesized …

British Gynaecological Cancer Society recommendations for evidence based, population data derived quality performance indicators for ovarian cancer

S Sundar, A Nordin, J Morrison, N Wood… - Cancers, 2023 - mdpi.com
Simple Summary Ovarian cancer survival in the UK is poorer than other similar countries.
Results from the National Ovarian Cancer Audit Feasibility Pilot (OCAFP) showed that …